Integer Holdings Corporation Reports Second Quarter 2026 Results

Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended July 3, 2026.

Second Quarter 2026 Highlights (compared to Second Quarter 2025, except as noted)

Sales decreased 2.6% to $464 million. Organic sales decreased 1.5%.

GAAP operating income from continuing operations totaled $35 million, a decrease of $25 million or 42%.

Non-GAAP adjusted operating income totaled $73 million, a decrease of $8 million or 10%.

GAAP income from continuing operations totaled $24 million, a decrease of $13 million or 36%.

Non-GAAP adjusted net income totaled $55 million, a decrease of $0.1 million or 0%.

GAAP diluted EPS income from continuing operations totaled $0.69, a decrease of $0.35 or 34%.

Non-GAAP adjusted EPS totaled $1.60, an increase of $0.05 or 3%.

Adjusted EBITDA totaled $95 million, a decrease of $4 million or 4%.

From the end of 2025, total debt increased $53 million to $1.238 billion and Non-GAAP net total debt increased $46 million to $1.236 billion, resulting in a leverage ratio of 3.2 times adjusted EBITDA as of July 3, 2026.

In a separate press release issued today, Integer and KKR announced they have entered into a definitive agreement under which an affiliate of investment funds managed by KKR will acquire all of the outstanding shares of Integer in an all-cash transaction valued at an enterprise value of $5.7 billion. Under the terms of the agreement, Integer stockholders will receive $127 per share in cash.

Given the pending transaction, Integer is withdrawing its previously issued financial outlook and will not host its previously scheduled earnings conference call and webcast scheduled for Thursday, August 6, 2026.

Discussion of Product Line Second Quarter 2026 Sales

Cardio & Vascular sales decreased 2% to $280 million in the second quarter 2026 compared to the second quarter 2025, reflecting the previously communicated impact from the two new Electrophysiology products.

Cardiac Rhythm Management & Neuromodulation sales increased 1% to $174 million in the second quarter 2026 compared to the second quarter 2025. Growth was partially offset by the previously communicated impact from the one new Neuromodulation product.

Other Markets sales totaled $10 million in the second quarter 2026, compared to $18 million in the second quarter 2025, primarily due to the Portable Medical exit.

Summary Financial Results (dollars in thousands, except per share data)

Three Months Ended Six Months Ended

July 3, 2026 June 27, 2025 QTD Change July 3, 2026 June 27, 2025 YTD Change

Operating income $ 34,528 $ 59,338 (41.8 )% $ 66,397 $ 108,890 (39.0 )%

Income from continuing operations $ 23,605 $ 37,009 (36.2 )% $ 40,111 $ 14,544 175.8 %

Diluted EPS from continuing operations $ 0.69 $ 1.04 (33.7 )% $ 1.17 $ 0.41 185.4 %

EBITDA (a) $ 67,964 $ 87,636 (22.4 )% $ 133,060 $ 119,274 11.6 %

Adjusted EBITDA (a) $ 94,939 $ 98,951 (4.1 )% $ 180,000 $ 190,460 (5.5 )%

Adjusted operating income (a) $ 72,991 $ 81,266 (10.2 )% $ 134,044 $ 152,189 (11.9 )%

Adjusted net income (a) $ 54,707 $ 54,818 (0.2 )% $ 96,002 $ 100,756 (4.7 )%

Adjusted EPS (a) $ 1.60 $ 1.55 3.2 % $ 2.80 $ 2.85 (1.8 )%

(a) EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are non-GAAP financial measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

Summary Product Line Results (dollars in thousands)

Three Months Ended July 3, 2026 June 27, 2025 QTD Change Organic Change (a) Product Line Sales...